Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 105-113

  Craig Jordan, V ^a   Lewis Wambi, Joan ^a   Kim, Helen ^a   Cunliffe, Heather ^b   Ariazi, Eric ^a   Sharma, Catherine G N ^a   Shupp, Heather A ^a   Swaby, Ramona ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Aromatase inhibitors; Gene array analysis; Raloxifene; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA; TAMOXIFEN;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CONCENTRATION RESPONSE; DNA METHYLATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; GENOMICS; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MOLECULAR CLONING; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR REGRESSION;

EID: 35648978885     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.020     Document Type: Article

References (72)

1. Jordan V.C., and Brodie A.M.H. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 (2007) 7-25
2. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 354 (1998) 1451-1467
3. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
4. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
5. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
6. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 5 (2007) 486-492
7. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
8. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
9. Jordan V.C., and Allen K.E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16 (1980) 239-251
10. Jordan V.C., and Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11 (1975) 205-206
11. Jordan V.C., Dix C.J., and Allen K.E. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant Therapy of Cancer 2 (1979) 19-26
12. Jordan V.C. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7 (2007) 46-53
13. Powles T.J., Hardy J.R., Ashley S.E., et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60 1 (1989) 126-131
14. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 13 (1992) 852-856
15. Love R.R., Wiebe D.A., Newcomb P.A., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115 11 (1991) 860-864
16. Cuzick J., and Baum M. Tamoxifen and contralateral breast cancer letter. Lancet 2 8449 (1985) 282
17. Fornander T., Rutqvist L.E., Cedermark B., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 8630 (1989) 117-120
18. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor- positive tumors. N Engl J Med 320 8 (1989) 479-484
19. Jordan V.C. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5 (1974) 354
20. Jordan V.C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA- induced rat mammary carcinoma. Eur J Cancer 12 (1976) 419-424
21. Gottardis M.M., and Jordan V.C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea- induced rat mammary carcinoma model. Cancer Res 47 15 (1987) 4020-4024
22. Jordan V.C., Lababidi M.K., and Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83 7 (1991) 492-496
23. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
24. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
25. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (2005) 1652-1662
26. 〈http://www.nature.com/milestones/milecancer/full/milecancer05.html〉
27. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 24 (1989) 1879-1886
28. Gail M.H., Costantino J.P., Bryant J., et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91 21 (1999) 1829-1846
29. Jordan V.C. Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. Eur J Cancer 42 (2006) 2909-2913
30. Veronesi U., Maisonneuve P., and Decensi A. Tamoxifen: an enduring star. J Natl Cancer Inst 99 4 (2007) 258-260
31. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 4 (2007) 272-282
32. Powles T.J., Ashley S., Tidy A., Smith I.E., and Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 4 (2007) 283-290
33. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., and Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48 (1988) 812-815
34. Jordan V.C. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36 4 (1984) 245-276
35. Jordan V.C., Phelps E., and Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10 1 (1987) 31-35
36. Jordan V.C. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest 6 5 (1988) 589-595
37. Lerner L.J., and Jordan V.C. The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50 (1990) 4177-4189
38. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial multiple outcomes of raloxifene evaluation (MORE) investigators [see comments] [published erratum appears in JAMA 1999 Dec 8;282(22):2124]. J Am Med Assoc 1999;282(7):637-45.
39. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. J Am Med Assoc 281 (1999) 2189-2197
40. Vogel V.G., Costantino J.P., Wickerham D.L., et al. The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. J Am Med Assoc 295 (2006) 2727-2741
41. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 2 (2006) 125-137
42. Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5 (2004) 207-213
43. Wolf D.M., and Jordan V.C. A laboratory model to explain the survival advantage observed in patients taking adjuvent tamoxifen therapy. Recent results in cancer research 127 (1993), Springer, Heidelberg 23-33
44. Gottardis M.M., and Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48 (1988) 5183-8187
45. Wijayaratne A.L., and McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276 (2001) 35684-35692
46. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20 16 (2002) 3386-3395
47. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 (2002) 3396-3403
48. Yao K., Lee E.S., Bentrem D.J., et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6 5 (2000) 2028-2036
49. Jelovac D., Macedo L., Goloubeva O.G., Handratta V., and Brodie A.M.H. additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 65 (2005) 5439-5444
50. Long B.J., Jelovac D., Handratta V., et al. therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. JNCI 96 (2004) 456-465
51. Berthois Y., Katzenellenbogen J.A., and Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83 8 (1986) 2496-2500
52. Katzenellenbogen B.S., Kendra K.L., Norman M.J., and Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47 (1987) 4355-4360
53. Welshons W.V., and Jordan V.C. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer 232 (1987) 1935-1939
54. Murphy C.S., Meisner L.F., Wu S.Q., and Jordan V.C. Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol 25 12 (1989) 1777-1788
55. Pink J.J., and Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56 10 (1996) 2321-2330
56. Pink J.J., Bilimoria M.M., Assikis J., and Jordan V.C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 74 8 (1996) 1227-1236
57. Bologa C.G., Revankar C.M., Young S.M., et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2 4 (2006) 207-212
58. Jiang S.Y., Wolf D.M., Yingling J.M., Chang C., and Jordan V.C. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endo 90 (1992) 77-80
59. Pink J.J., Jiang S.Y., Fritsch M., and Jordan V.C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res 55 (1995) 2583-2590
60. Cormier E.M., and Jordan V.C. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur J Cancer Clin Oncol 25 1 (1989) 57-63
61. Robinson S.P., and Jordan V.C. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. Eur J Cancer Clin Oncol 25 (1989) 493-497
62. Cormier E.M., Wolf M.F., and Jordan V.C. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 49 (1989) 576-580
63. Ingle J.N., Suman V.J., Rowland K.M., et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24 7 (2006) 1052-1056
64. Lonning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67 (2001) 111-116
65. Song R.X., Mor G., Naftolin F., et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93 (2001) 1714-1723
66. Lewis J.S., Osipo C., Meeke K., and Jordan V.C. Estradiol induced apoptosis in a breast cancer cell line resistant to estrogen deprivation. J Steroid Biochem 94 1-3 (2005) 131-141
67. Gottardis M.M., Jiang S.Y., Jeng M.H., and Jordan V.C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49 15 (1989) 4090-4093
68. Wolf D.M., Langan-Fahey S.M., Parker C.J., McCague R., and Jordan V.C. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85 10 (1993) 806-812
69. MacGregor-Schafer J.I., Lee E.-S., O'Regan R.M., Yao K., and Jordan V.C. Rapid development of tamoxifen stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 6 (2000) 4373-7380
70. Osipo C., Meeke K., Liu H., et al. Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. Cancer Res 65 18 (2005) 8504-8513
71. Osipo C., Gajdos C., Liu H., Chen B., and Jordan V.C. Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95 (2003) 1597-1607
72. Liu H., Lee E.S., Gajdos C., et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95 21 (2003) 1586-1597